Free Delivery Over $100
|
|
|||
|
||||
OverviewMerck and the pharmaceutical industry are headline news today. Controversies over public safety, prices, and the ability of the industry to develop the new drugs and vaccines that society needs have been covered worldwide. Roy Vagelos, who was head of research and then CEO at Merck from the mid-1970s through the early 1990s, addresses these issues here. Success with targeted research started Merck on a path that would lead to a series of block-buster therapies that carried the firm to the top of the global industry in the 1990s and Vagelos into the top position at the company. Trained as a physician and scientist, he had to learn how to run a successful business while holding to the highest principles of ethical behavior. He was not always successful. He and his co-author explain where and why he failed to achieve his goals and carefully analyze where he succeeded. Full Product DetailsAuthor: P. Roy Vagelos , Louis GalambosPublisher: Cambridge University Press Imprint: Cambridge University Press (Virtual Publishing) ISBN: 9780511616860ISBN 10: 0511616864 Publication Date: 05 June 2012 Audience: College/higher education , Professional and scholarly , General/trade , Tertiary & Higher Education , Professional & Vocational Format: Undefined Publisher's Status: Active Availability: In stock  We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately. Table of ContentsReviewsAuthor InformationP. Roy Vagelos is retired Chairman of Merck and Co., Inc.; Chairman of Regeneron Pharmaceuticals Inc.; and Chairman of Theravance Corporation. Louis Galambos is Professor of History at The Johns Hopkins University in Baltimore, Maryland and the editor of The Papers of Dwight David Eisenhower. He is the coauthor of Networks of Innovation (Cambridge, 1995) and Anytime, Anywhere (Cambridge, 2002). Tab Content 6Author Website:Countries AvailableAll regions |
||||
